Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07229261
NA

MitoQ to Improve Vascular Funciton in Preeclampsia

Sponsor: Medical College of Wisconsin

View on ClinicalTrials.gov

Summary

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with gestational hypertension (gHTN) and/or preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with gHTN and/or preeclampsia could translate into a viable therapeutic option.

Official title: MitoQ (Mitoquinol Mesylate) to Ameliorate Vascular Function in Preeclampsia: a Novel Approach

Key Details

Gender

FEMALE

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-03-18

Completion Date

2027-09-30

Last Updated

2026-10-02

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Mitoquinol Mesylate

Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.

OTHER

Placebo

Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Locations (1)

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States